Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Vir Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 258.29%.
The historical rank and industry rank for Vir Biotechnology's ROC (Joel Greenblatt) % or its related term are showing as below:
MEX:VIR'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1586.16 Med: -377.5 Max: 523.58
Current: -225.1
During the past 9 years, Vir Biotechnology's highest ROC (Joel Greenblatt) % was 523.58%. The lowest was -1586.16%. And the median was -377.50%.
MEX:VIR's ROC (Joel Greenblatt) % is ranked better than 53.66% of 1325
companies
in the Biotechnology industry
Industry Median: -307.32
vs MEX:VIR: -225.10
Vir Biotechnology's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Vir Biotechnology (MEX:VIR) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Vir Biotechnology ROC (Joel Greenblatt) % Related Terms
Vir Biotechnology ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Vir Biotechnology's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VIR vs AVBP, XNCR, SEPN: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Vir Biotechnology's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's ROC (Joel Greenblatt) % falls into.
Vir Biotechnology ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 258.29% mean?
Vir Biotechnology (MEX:VIR) has a ROC (Joel Greenblatt) % of 258.29% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vir Biotechnology and its competitors. According to the industry distribution chart, Vir Biotechnology ranks #614 out of 1325 companies in the Biotechnology industry, placing it in the top 46.3%.
Is Vir Biotechnology's ROC (Joel Greenblatt) % too high?
Vir Biotechnology's current ROC (Joel Greenblatt) % is 258.29%. Based on the distribution chart, Vir Biotechnology ranks #614 out of 1325 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vir Biotechnology has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's ROC (Joel Greenblatt) % compare to AVBP and XNCR?
According to the Biotechnology industry distribution chart, Vir Biotechnology ranks #614 out of 1325 companies for ROC (Joel Greenblatt) %. This puts Vir Biotechnology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vir Biotechnology and its competitors. Vir Biotechnology's current ROC (Joel Greenblatt) % is 258.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Vir Biotechnology (MEX:VIR) has a current ROC (Joel Greenblatt) % of 258.29%. The stock's GF Value™ is MXN764.28, compared to a current price of MXN170.00 — trading 77.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 258.29%. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Vir Biotechnology (MEX:VIR), the current ROC (Joel Greenblatt) % is 258.29% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (MEX:VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of MXN170.00 is trading 77.8% below its estimated GF Value™ of MXN764.28.
Key valuation signals for MEX:VIR:
ROC (Joel Greenblatt) %: 258.29%
GF Value™: MXN764.28 vs. price of MXN170.00 (77.8% below fair value)
No single metric tells the full story. See the MEX:VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score
Get the complete analysis for MEX:VIR
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VIR has been successfully added to your 
